Similarly, the development of a first-in-class anti-cancer dual HDAC2/FAK inhibitor featuring hydroxamates/benzamides capped by pyridinyl-1, 2, 4-triazoles further emphasizes the importance of simultaneous targeting of multiple pathways critical for tumor growth. The gene discussed is HDAC2; the disease is cancer.